Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Olteanu, N. Karandikar, R. Mckenna, Yin Xu (2006)
Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow.American journal of clinical pathology, 126 5
S. Richards, A. Hill, P. Hillmen (2007)
Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuriaCytometry Part B: Clinical Cytometry, 72B
A. Hill, P. Hillmen, S. Richards, D. Elebute, J. Marsh, Jason Chan, C. Mojcik, R. Rother (2005)
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.Blood, 106 7
Hillmen (2006)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobuniriaEngl J Med
K. Nafa, M. Bessler, H. Castro-Malaspina, S. Jhanwar, L. Luzzatto (1998)
The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications.Blood cells, molecules & diseases, 24 3
C. Parker, M. Omine, S. Richards, J. Nishimura, M. Bessler, R. Ware, P. Hillmen, L. Luzzatto, N. Young, T. Kinoshita, W. Rosse, G. Socié (2005)
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.Blood, 106 12
Borowitz (2010)
On behalf of the Clinical Cytometry Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry PartSociety Cytometry Clin, 30
P. Blaas, S. Weber, G. Hänsch, H. Peter (1990)
[Paroxysmal nocturnal hemoglobinuria].Klinische Wochenschrift, 68 5
D. Sutherland, Nancy Kuek, Jeff Davidson, D. Barth, Hong Chang, E. Yeo, Sylvia Bamford, I. Chin-Yee, M. Keeney (2007)
Diagnosing PNH with FLAER and multiparameter flow cytometryCytometry Part B: Clinical Cytometry, 72B
S. Oni, B. Osunkoya, L. Luzzatto (1970)
Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells.Blood, 36 2
Bessler (1994)
Paroxysmal nocturnal hemoglobinuria is caused by somatic mutations in the PIG geneEMBO J, 13
Sa Wang, O. Pozdnyakova, J. Jorgensen, L. Medeiros, Dariusz Stachurski, Mary Anderson, A. Raza, B. Woda (2009)
Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveatsHaematologica, 94
N. Galili, F. Ravandi, G. Palermo, J. Bubis, A. Illingworth, H. Castro-Malaspina, A. Raza (2016)
Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
P. Hillmen, P. Muus, U. Dührsen, A. Risitano, J. Schubert, L. Luzzatto, H. Schrezenmeier, J. Szer, R. Brodsky, A. Hill, G. Socié, M. Bessler, S. Rollins, L. Bell, R. Rother, N. Young (2007)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.Blood, 110 12
P. Hillmen, N. Young, J. Schubert, R. Brodsky, G. Socié, P. Muus, A. Röth, J. Szer, M. Elebute, R. Nakamura, P. Browne, A. Risitano, A. Hill, H. Schrezenmeier, C. Fu, J. Maciejewski, S. Rollins, C. Mojcik, R. Rother, L. Luzzatto (2006)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.The New England journal of medicine, 355 12
E. Schoot, T. Huizinga, E. Veer-Korthof, Rosemarie Wijmans, J. Pinkster, A. Borne (1990)
Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay.Blood, 76 9
Mayur Movalia, A. Illingworth (2009)
Identification and Clinical Significance of Type II Granulocytes Among Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Identified Using Multiparameter High-Sensitivity Flow Cytometry.Blood, 114
S. Richards, A. Rawstron, P. Hillmen (2000)
Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria.Cytometry, 42 4
V. Moyo, G. Mukhina, Elizabeth Garrett, R. Brodsky (2004)
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assaysBritish Journal of Haematology, 126
M. Borowitz, F. Craig, Joseph DiGiuseppe, A. Illingworth, W. Rosse, D. Sutherland, C. Wittwer, S. Richards (2010)
Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometryCytometry Part B: Clinical Cytometry, 78B
I. Marinov, M. Kohoutová, V. Tkáčová, D. Lysák, M. Holubová, O. Stehlikova, Tatiana Železníková, D. Žontar, A. Illingworth (2013)
Intra‐ and interlaboratory variability of paroxysmal nocturnal hemoglobinuria testing by flow cytometry following the 2012 Practical Guidelines for high‐sensitivity paroxysmal nocturnal hemoglobinuria testingCytometry Part B: Clinical Cytometry, 84B
D. Sutherland, M. Keeney, A. Illingworth (2012)
Practical guidelines for the high‐sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometryCytometry Part B: Clinical Cytometry, 82B
(2009)
Use of FLAER-based white blood cell assay in the primary screening of PNH clones
AbstractBackground: Evaluation of paroxysmal nocturnal hemoglobinuria (PNH) clones by flow cytometry (FCM) is not standardized and is associated with consistent inter-laboratory variability.Methods: In order to rule out the influence of particular approach in generating final results, we analyzed the performance characteristics of individual consensus strategies for small to intermediate (1%–20%) and minor (<1%) PNH clones within the white blood cell (WBC) and red blood cell (RBC) compartments with sensitivity up to 0.1%.Results: Coefficient of variation (CV) for precision/reproducibility analysis ranged from 0.67%/1.49% to 2.56%/3.09% for granulocytes, from 0.93%/3.09% to 7.76%/12.06% for monocytes and from 0.41%/4.73% to 6.53%/5.1% for RBCs. Coefficient of determination (r2) for linear regression analysis ranged from 0.95 to 0.99, Wilcoxon ranks test showed no statistically significant differences (p>0.05), Bland-Altman analysis demonstrated performance agreement with mean bias ranging from −0.18 to 1.24.Conclusions: Our results confirmed very good performance characteristics for precision and reproducibility analysis, excellent correlation and favorable agreement between strategies, suggesting that reported inter-laboratory variability is related mainly to incorrect performance and/or insufficient experience with PNH testing by flow cytometry, rather than to relevant limitations of any particular approach.
Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter
Published: Nov 1, 2013
Keywords: consensus approaches; flow cytometry; paroxysmal nocturnal hemoglobinuria (PNH); performance characteristics
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.